Clinical Trials Logo

Traumatic Brain Injury clinical trials

View clinical trials related to Traumatic Brain Injury.

Filter by:

NCT ID: NCT06330935 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Evaluating the Effect of Tranexamic Acid on the Clinical Outcomes in Patients With Traumatic Brain Injury

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the effect of tranexamic acid on mortality in pediatric patients with traumatic brain injury. This could potentially lead to improved treatment protocols and better outcomes for this vulnerable population.

NCT ID: NCT06328985 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Intermittent Oro-esophageal Tube Feeding in Traumatic Brain Injury Patients

Start date: March 2024
Phase: N/A
Study type: Interventional

This was a multicenter randomized controlled study of 98 severe Traumatic Brain Injury patients with tracheostomy. Patients enrolled were divided randomly into the observation group with Intermittent Oro-esophageal Tube Feeding or the control group with Nasogastric tube feeding for enteral nutrition support, respectively. Nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

NCT ID: NCT06328309 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Impact of v Release on Dysphagia in Patients With Traumatic Brain Injury

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore Clinical Effect of Myofascial Release Therapy in Dysphagic Traumatic Brain injured Survivors. The main question it aims to answer is: • Can Myofascial Release Therapy improve swallowing function in Traumatic Brain injured Survivors? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Myofascial Release Therapy. The study lasts 21 days for each patient. Researchers will compare the Functional Oral Intake Scale, Penetration-Aspiration Scale, Swallowing Quality of Life to see if the Myofascial Release Therapy can help improve the situation.

NCT ID: NCT06319638 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Efficacy of Stellate Ganglion Block in Traumatic Brain Injury Patients

Start date: May 2024
Phase: N/A
Study type: Interventional

The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in Traumatic Brain Injury Patients. The main question it aims to answer are: Can stellate ganglion block improve the dysphagia and activities of daily living in Traumatic Brain Injury Patients. Traumatic Brain Injury Patients will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

NCT ID: NCT06311604 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Evaluation of the Safety of Inhaled Sedation With Isoflurane in Head Trauma Patients

IsoSAFE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Intensive care management of patient with severe traumatic brain injury (TBI) includes deep and prolonged sedation with intravenous hypnotics (propofol, midazolam, ketamine) in combination with opioids to prevent and/or treat episodes of intracranial hypertension. However, some patients may develop tachyphylaxis with a gradual increase of administered intravenous hypnotics and opioids to maintain the same level of sedation. This situation leads to a failure in controlling intracranial pressure (ICP) and/or to the risk of adverse effects due to high-dose sedatives: haemodynamic instability, prolonged mechanical ventilation, neuromyopathy, delirium, withdrawal syndrome. Halogenated agents (Isoflurane, Sevoflurane) are a class of hypnotics routinely used in the operating room. However, doses used in surgical patients (> 1 Minimal Alveolar Concentration, MAC) are not suitable in neuro-intensive care unit (ICU) patients at risk of intracranial hypertension because of the cerebral vasodilator effects of halogenated agents at this dosage, hence the risk of high ICP and compromised cerebral perfusion pressure. The use of halogenated agents has been recently possible in the ICU through dedicated medical devices (Sedaconda ACD, Mirus). Recommended dosage are lower in the ICU, i.e. 0.3-0.7 MAC, because of their association with intravenous hypnotics and the absence of surgical stimuli. Several clinical studies in general ICUs showed improved sedation quality, reduced duration of mechanical ventilation, faster arousal and shorter extubation time, and lower costs in halogenated group compared with control group receiving midazolam or propofol. At low doses, the effects on ICP and intracerebral haemodynamics of halogenated agents are minor according to the available literature. In addition, beneficial effects were found on cerebral ischaemic volume in animal models treated with halogenated agents. However, there is a need to explore the benefit-risk ratio of the use of halogenated agents in the severe TBI population. The investigator hypothesise that 0.7 MAC Isoflurane can be administered in this population without deleterious effect on ICP.

NCT ID: NCT06304116 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Effect of Lidocaine Block in Traumatic Brain Injury

Start date: March 2024
Phase: N/A
Study type: Interventional

The goal of this or clinical trial is to explore efficacy of stellate ganglion block on dysphagia and activities of daily living in Traumatic Brain Injury Patients. The main question it aims to answer are: Can stellate ganglion block improve the dysphagia and activities of daily living in Traumatic Brain Injury Patients. Traumatic Brain Injury Patients will be divided into the the control group and observation group evenly. All the patients were provided with routine therapy, while the patients in the observation group were given stellate ganglion block. The swallowing function, and activities of daily living of the two groups of patients before and after treatment were evaluated.

NCT ID: NCT06304012 Completed - Clinical trials for Traumatic Brain Injury

Effect of Oral Enteral Nutrition on Severe Traumatic Brain Injury

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This was a multicenter randomized controlled study of 98 severe Traumatic Brain Injury patients with tracheostomy. Patients enrolled were divided randomly into the observation group with Intermittent Oro-esophageal Tube Feeding (n=50) or the control group with Nasogastric tube feeding (n=48) for enteral nutrition support, respectively. Nutritional status, complications, decannulation of tracheostomy tubes and level of consciousness on day 1 and day 28 were recorded and compared.

NCT ID: NCT06297044 Active, not recruiting - Healthy Clinical Trials

Neural and Cognitive Correlates of Pragmatic Abilities

APACS_Neuro
Start date: March 29, 2018
Phase:
Study type: Observational

Pragmatics of language refers to the set of abilities that allow one to use and interpret language according to context and, in general, to communicate effectively. Disorders in the pragmatics of language are prevalent in various clinical populations. They are a cause of social withdrawal and worse quality of life, both for patients directly affected and for their family members. Despite this, this type of disorder is rarely considered in neuropsychological assessment and rehabilitation. This study's objective is to characterize pragmatic deficits in various neurological populations, allowing for the most accurate diagnosis possible and leading to the planning of personalized and effective Rehabilitation Plans.

NCT ID: NCT06293300 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.

NCT ID: NCT06292585 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)

Start date: March 2024
Phase: N/A
Study type: Interventional

A prospective, multicenter, randomized controlled, open-label, blinded endpoint evaluation study.